Transverses Abdominis Plane Block Versus Local Wound Infiltration in Total Abdominal Hysterectomy
1 other identifier
interventional
100
1 country
1
Brief Summary
To compare the transverses abdominis plane block outcome versus local wound infiltration for postoperative analgesia in patients undergoing total abdominal hysterectomy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable pain
Started Dec 2023
Shorter than P25 for not_applicable pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2023
CompletedFirst Submitted
Initial submission to the registry
February 1, 2024
CompletedFirst Posted
Study publicly available on registry
February 13, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2024
CompletedJuly 25, 2024
July 1, 2024
3 months
February 1, 2024
July 24, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Pain score
Pain score will be evaluated through Visual analogue scale (VAS) score of 0-10cms.
24 hours of surgery.
Secondary Outcomes (1)
Analgesia consumption
During 24 hours of surgery
Study Arms (2)
Transverses abdominis plane block
EXPERIMENTALLocal wound infiltration
ACTIVE COMPARATORInterventions
Transverses abdominis plane block will be provided randomly using prospective double-blinding.
Local wound infiltration will be provided randomly using prospective double-blinding.
Eligibility Criteria
You may qualify if:
- Age range 18 to 50 years
- Female
- ASA I \& II
- Undergoing Abdominal Hysterectomy under General anaesthesia
You may not qualify if:
- Hepatic failure (assessed on clinical signs and symptoms, elevated liver enzymes and ultrasound findings showing loss of normal texture of liver) or renal failure (a GFR of 15 or less)
- Allergy or contraindication to study drugs on history
- Drug abuse or addiction
- Bleeding tendency
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dr Muhammad Ariflead
Study Sites (1)
Muhammad Arif
Karachi, Sindh, Pakistan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Muhammad Arif
Ziauddin University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 1, 2024
First Posted
February 13, 2024
Study Start
December 1, 2023
Primary Completion
February 28, 2024
Study Completion
February 28, 2024
Last Updated
July 25, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will not share